As new medications enter the market, we’ve observed a troubling new trend: an influx of clinically superfluous brand drugs that carry hefty price tags but offer little to no added clinical value.
Recently, manufacturers have launched new brand-name prescription wound dressings that include similar combinations of ingredients as OTC and lower-cost generic products yet are priced far higher than the alternatives — up to 125 times more.
This report shines a spotlight on the latest category: Wound care.
Related healthcare insights
Article
Michael Einodshofer addresses the risks, challenges and opportunities facing the industry.
Article
Optum offers an infographic to help hospitals better understand true growth potential and the potential impact of physician outreach.